FIELD: medicine.
SUBSTANCE: invention refers to medicine and concerns the use of bis-(N-monosuccinyl-L-seryl-L-lysine) hexamethylene diamide as an agent for treating opioid dependence.
EFFECT: invention provides treating opioid dependence.
1 cl, 2 dwg, 1 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
DIMERIC DIPEPTIDE MIMETIC BDNF AS AGENT FOR TREATING AND PREVENTING OPIOID ADDICTION | 2023 |
|
RU2823374C1 |
LOW MOLECULAR WEIGHT MIMETIC OF BRAIN NEUROTROPHIC FACTOR WITH ANALGESIC, ANXIOLYTIC AND ANTIADDICTIVE EFFECTS | 2020 |
|
RU2759023C2 |
PHARMACEUTICAL COMPOSITION BASED ON BIS-(N-MONOSUCCINYL-L-SERYL-L-LYSINE) HEXAMETHYLENEDIAMIDE (GSB-106) | 2018 |
|
RU2697254C1 |
DIMERIC DIPEPTIDE MIMETICS OF NEUROTROFIN-3 | 2022 |
|
RU2800369C1 |
MEANS FOR OPIOID ABSTINENCE SYNDROME ARRESTING | 2017 |
|
RU2643588C1 |
MEDICATION FOR WITHDRAWAL SYNDROME MANAGEMENT IN OPIATE DEPENDENCE | 2012 |
|
RU2485954C1 |
ANALGESIC AGENT AND THERAPY OF PAIN SYNDROME OF VARIOUS AETIOLOGIES BY USING SAID AGENT | 2007 |
|
RU2367432C2 |
COMPOSITIONS AND METHODS OF PREVENTING AND TREATING ADDICTIONS | 2008 |
|
RU2492858C2 |
AGENT POSSESSING ANTIDIABETIC ACTIVITY | 2017 |
|
RU2693479C2 |
IMMUNOGEN FOR TREATING AND PREVENTING OPIATE ADDICTION | 2013 |
|
RU2548802C1 |
Authors
Dates
2019-11-26—Published
2019-05-17—Filed